Home
 


Pan African Clinical Trials Registry
South African Medical Research Council, South African Cochrane Centre
PO Box 19070, Tygerberg, 7505, South Africa
Telephone: +27 21 938 0506 / +27 21 938 0834     Fax: +27 21 938 0836
Email: pactradmin@mrc.ac.za     Website: www.pactr.org

Trial no.: PACTR201204000362870 Date registered: 2012/02/26
TRIAL DESCRIPTION
Public title Safety of Malaria vaccines in Gambian children
Official scientific title Safety and immunogenicity of a heterologous prime-boost vaccine strategy with AdCh63 ME-TRAP and MVA ME-TRAP in children in a malaria endemic area
Brief summary describing the background
and objectives of the trial
A phase 1 study to assess the safety and immunogenicity of a heterologous prime-boost vaccine strategy with AdCh63 ME-TRAP and MVA ME-TRAP in 36 healthy children aged 2-6 years in a malaria endemic area. Safety was assessed by clinical evaluations post vaccination, and immunogenicity was assessed by ELISPOT assay and intra-cellular cytokine staining by flow cytometry.
Type of trial RCT
Acronym (If the trial has an acronym then please provide)
Disease(s) or condition(s) being studied Malaria ,
Purpose of the trial Prevention
Anticipated trial start date 2010-06-14
Actual trial start date 2010-06-14
Anticipated date of last follow up 2011-12-22
Actual date of last follow up 2011-12-22
Anticipated target sample size (number of participants) 36   
Actual target sample size (number of participants) 36   
Recruitment status Closed to recruitment: follow up complete
Secondary Ids Issuing authority/Trial register Links to Secondary ID

STUDY DESIGN
Intervention assignment Allocation to intervention If randomised, describe how the allocation sequence was generated Describe how the allocation sequence/code was concealed from the person
allocating the participants to the intervention arms
Masking If masking / blinding was used
Parallel: different groups receive different interventions at same time during study Randomised Simple randomisation using a radomisation table created by a computer software program Allocation was determined by the holder of the sequence who is situated off site Open-label (masking not used)

INTERVENTIONS
Intervention type Intervention name Dose Duration Intervention description Group size Nature of control
Experimental group AdCh63 ME-TRAP followed by MVA ME-TRAP 8 weeks later AdCh63 ME-TRAP 1 x 1010vp IM followed by MVA ME-TRAP 1 x 108 pfu IM 8 weeks later AdCh63 ME-TRAP 1 x 1010vp IM followed by MVA ME-TRAP 1 x 108 pfu IM 8 weeks later malaria vaccine 6
Experimental group AdCh63 ME-TRAP and MVA ME-TRAP AdCh63 ME-TRAP 1 x 1010vp IM followed by MVA ME-TRAP 2 x 108 pfu IM 8 weeks later AdCh63 ME-TRAP 1 x 1010vp IM followed by MVA ME-TRAP 2 x 108 pfu IM 8 weeks later 6
Experimental group AdCh63 ME-TRAP and MVA ME-TRAP AdCh63 ME-TRAP 5 x 1010vp IM followed by MVA ME-TRAP 2 x 108 pfu IM 8 weeks later AdCh63 ME-TRAP 5 x 1010vp IM followed by MVA ME-TRAP 2 x 108 pfu IM 8 weeks later 6
Control group HDCRV HDCRV 1ml IM followed by HDCRV 1ml IM 8 weeks later HDCRV 1ml IM followed by HDCRV 1ml IM 8 weeks later Rabies vaccine 6 Placebo
Experimental group AdCh63 ME-TRAP and MVA ME-TRAP AdCh63 ME-TRAP 1 x 1010vp followed byMVA ME-TRAP 1 x 108 pfu 10 months malaria vaccine 6
Experimental group AdCh63 ME-TRAP and MVA ME-TRAP AdCh63 ME-TRAP 1 x 1010vp followed by MVA ME-TRAP 2 x 108 pfu 10 months malaria vaccine 6

ELIGIBILITY CRITERIA
List inclusion criteria List exclusion criteria Min age Max age Gender
¿ A male or female between, and including, 2 and 6 years of age at the time of the first vaccination. ¿Written informed consent obtained from the subject¿s parents. ¿Free of obvious health problems as established by medical history and clinical examination before entering into the study. ¿Availability for the duration of the immunization and follow-up period. ¿Clinically significant history of skin disorder (psoriasis, contact dermatitis etc.), allergy, symptomatic immunodeficiency, cardiovascular disease, respiratory disease, endocrine disorder, liver disease, renal disease, gastrointestinal disease, neurological illness. ¿Severe malnutrition, defined as weight-for-height z-score <-3 or oedema of both feet (WHO) ¿Hypersensitivity to HDCRV. ¿History of allergic disease or reactions likely to be exacerbated by any component of the vaccines, e.g. egg products, Kathon, neomycin, betapropiolactone. ¿History of splenectomy. ¿Haemoglobin less than 9.0 g/dL ¿Serum creatinine concentration above >130mmol/L ¿Serum ALT concentration >69 IU/L ¿Blood transfusion within one month of enrolment. ¿History of vaccination with previous experimental malaria vaccines. ¿Administration of any other vaccine or immunoglobulin within two weeks before vaccination. ¿Current participation in another clinical trial, or within 12 weeks of this study. ¿Any other finding which in the opinion of the investigators would increase the risk of an adverse outcome from participation in the trial. ¿Likelihood of travel away from the study area. ¿HIV positive. 2 Years 6 Years Both

ETHICS APPROVAL
Has the study received appropriate ethics committee approval Date the study will be submitted for approval Date of approval
Name of the ethics committee
Yes 2010/12/14 The Gambia Government /MRC Joint Ethics Committee
Ethics Committee Address
Street address City Postal code Country
MRC Unit, Atlantic Boulevard Fajara PO Box 273 Gambia

OUTCOMES
Type of outcome Outcome Timepoint(s) at which outcome measured
Primary Outcome ¿Occurrence of solicited events after each vaccination over a 3-day follow-up period
Primary Outcome ¿ Occurrence of unsolicited symptoms after each vaccination over a 30-day follow-up
Primary Outcome ¿Occurrence of solicited events after each vaccination over a 3-day follow-up period
Primary Outcome ¿ Occurrence of unsolicited symptoms after each vaccination over a 30-day follow-up period (day of vaccination and 29 subsequent days)

RECRUITMENT CENTRES
Name of recruitment centre Street address City Postal code Country
MRC Unit Atlantic Boulevard Fajara PO Box 273 Gambia

FUNDING SOURCES
Name of source Street address City Postal code Country
EDCTP 334 Laan van Nieuw Oost Indië The Hague P.O.Box 93015, 2509 Netherlands

SPONSORS
Sponsor level Name Street address City Postal code Country Nature of sponsor
Primary Sponsor University of Oxford Manor House Oxford Oxford, OX3 9DZ United Kingdom University

COLLABORATORS
Name Street address City Postal code Country
European Vaccine Initiative UniversitätsKlinikum Heidelberg Heidelberg 69120 Germany

CONTACT PEOPLE
Role Name Email Phone Fax
Principal Investigator Dr Kalifa Bojang kbojang@mrc.gm 2204495442 x4004 +220 4495919
Street address City Postal code Country Position / Affiliation
Atlantic Boulevard Fajara PO BOx273 Gambia Senior Clinical scientist
Role Name Email Phone Fax
Public Enquiries Ms Mamkumba Sanneh msanneh@mrc.gm 2204495442 x2315 +220 4495919
Street address City Postal code Country Position / Affiliation
Atlantic Boulevard Fajara PO BOx273 Gambia Programme Manager
Role Name Email Phone Fax
Scientific Enquiries Dr Muhammed Afolabi mafolabi@mrc.gmm 2204495442 x5037 +220 4495919
Street address City Postal code Country Position / Affiliation
Atlantic Boulevard Fajara PO BOx273 Gambia Clinical scientist